PharmExec Blog

Trending: Wearables and Invisibles

wearableI can’t help imagining the cocktail party of 2018 as a scene from one of those a low-budget sci-fi film aired late at night. Imagine: A living room packed with people too busy to chat with each other as they balance their drinks with one hand and monitor their sleeves of devices and smartphones with the other — emailing, texting checking their wearable ECGs (electrocardiograms); glucose monitors and even insulin pumps.

A new report by Juniper Research, Smart Health & Fitness Wearables: Device Strategies, Trends & Forecasts 2014-2019, found that fitness wearables in-use will almost treble by 2018, compared to an estimated 19 million in-use devices this year. Sam Smith of Juniper Research said that fitness devices are expected to remain the dominant wearable segment, driven by intuitive use cases and lower retail prices. However, beyond 2018, the broader appeal of smart watches will mean that they will be used more frequently in later years.” Read More »

Posted in Op-Ed, Technology | Tagged , , , | Leave a comment

Risking It All? Risk-Based Monitoring at Cancer Research UK

“Only those who risk going too far can possibly find out how far they can go,” said T.S. Elliot. Cancer Research UK (CRUK) followed this advice when it decided to have its Center for Drug Development (CDD) adopt a risk-based monitoring (RBM) approach across its entire portfolio of clinical trials. This decision has revealed how risk-adjusted approaches can bring greater than 20% efficiency savings in the monitoring of early phase oncology trials, which were previously believed to be unsuitable for RBM.

Sherraine Hurd explains the process of moving to RBM in this Applied Clinical Trials article.

Posted in R&D, Strategy | Tagged , , , , | Leave a comment

The Year of Living Openly: Europe and Transparency 2015

The past year has brought significant changes not only in regulatory mandates and guidances but also regarding a broader overall emphasis on coordination of information and processes.

The regulators have prioritized transparency and harmonization for some time but underscored them to an even greater degree in 2014; 2015 is likely to see the trend intensify. Read More »

Posted in compliance, Europe, Global, Guest Blog | Tagged , , , , , , | Leave a comment

‘Warehousing’ and the Future of HCV Treatment

The battle against hepatitis C (HCV) is a relatively new, and highly dynamic, one. 

The viral disease was only discovered in the 1980’s and, according to WHO estimates, some 3% of the world’s population are now infected with HCV and there are more than 170 million chronic carriers.

So what does the HCV treatment landscape look like and why is it so topical right now? Read More »

Posted in healthcare, Strategy | Tagged , , | Leave a comment

Dental Health: The Heart-Disease Puzzle’s Missing Piece?

“At least she has her teeth,” my grandmother would say when gossiping about a friend. My grandmother had none of her’s and took her dentures out every night and put them in a glass of water by her bed.

Growing up it was clear to me that dental health did not afford the same import as physical health. That is, until my father died of dental related disease.

He had not known he had had rheumatic fever as a youngster, and so he was not given the precautionary shot of penicillin when having a tooth capped. He contracted an infection in his heart and died shortly afterwards of subacute bacterial endocarditis.  Read More »

Posted in healthcare | Tagged , , | Leave a comment
  • Categories

  • Meta